business
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Key takeaways
- VIR SVRA URGN SMMT IMVT Superstring Capital Management disclosed a new position in Vir Biotechnology (NASDAQ:VIR), acquiring 730,548 shares in the first quarter.
- Securities and Exchange Commission dated May 14, 2026, Superstring Capital established a new position in Vir Biotechnology with 730,548 shares purchased.
- NASDAQ: SMMT: $16.93 million (12.1% of AUM)
VIR SVRA URGN SMMT IMVT Superstring Capital Management disclosed a new position in Vir Biotechnology (NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing.
According to a filing with the U.S. Securities and Exchange Commission dated May 14, 2026, Superstring Capital established a new position in Vir Biotechnology with 730,548 shares purchased. The estimated transaction value was $5.82 million, based on the mean unadjusted closing price for the first quarter of 2026. The fund’s quarter-end position in Vir Biotechnology was valued at $6.55 million, reflecting both trading activity and price appreciation.
NASDAQ: SMMT: $16.93 million (12.1% of AUM)
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Investing.com
CrowdStrike’s SWOT analysis: stock eyes growth amid AI shifts
Investing.com
Northern Trust’s SWOT analysis: stock outlook amid rising targets
Investing.com
Baidu’s SWOT analysis: stock faces mixed outlook amid AI push
Al Jazeera
Thousands rally in Taiwan to boost defence spending amid China tensions
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop